Keyphrases
Omalizumab
33%
Contact Dermatitis
33%
Hydroxyzine
33%
Severe Uncontrolled Asthma
33%
Asthma
32%
COVID-19
25%
Ethylenediamine
19%
Common Variable Immunodeficiency
19%
Blood Eosinophil Count
18%
White Patients
18%
Observational Longitudinal Study
18%
Tree Pollen
16%
Urban Centers
16%
Oral Aspirin Challenge
16%
Pollen Count
16%
Hydrocortisone
16%
Severe Coronavirus Disease 2019
16%
Dichlorophenol
16%
Black Men
16%
Tezepelumab
16%
Eosinophilia
16%
Chronic Urticaria
16%
Urticaria
16%
Airway Assessment Tests
16%
Absolute Eosinophil Count
16%
Asthma Patients
16%
Anosmia
16%
Antibody Deficiency
16%
Allergic Comorbidity
16%
Long-term Efficacy
16%
Functional Antibodies
16%
Gaucher Disease
16%
Mugwort
16%
Corticosteroid-sparing
16%
Takayasu Arteritis
16%
Allergic Asthma
16%
Treatable Traits
16%
Illness
16%
Cytokine Storm Syndrome
16%
Young Age
16%
Benralizumab
16%
Skin Prick
16%
15-hydroxyeicosatetraenoic Acid
16%
Rash
16%
Uncontrolled Severe Asthma
16%
Long-term Safety
16%
Randomized Placebo-controlled Trial
16%
Fever
16%
Ageusia
16%
Chronic Obstructive Pulmonary Disease
14%
Medicine and Dentistry
Asthma
66%
COVID-19
50%
Hydroxyzine
33%
Contact Dermatitis
33%
Tezepelumab
33%
Eosinophil
33%
Disease
18%
Chronic Urticaria
16%
Urticaria
16%
Hydrocortisone
16%
Artemisia vulgaris
16%
Exanthem
16%
Anosmia
16%
Environmental Allergy
16%
Benralizumab
16%
Cytokine Storm
16%
Eosinophilia
16%
Placebo
16%
Ageusia
16%
Ethylenediamine
14%
Odds Ratio
11%
Symptom
11%
Neomycin
9%
Patient with Asthma
8%
Allergic Response
8%
Adverse Event
7%
Emergency Department
6%
Chronic Obstructive Pulmonary Disease
6%
Dermatology Life Quality Index
6%
Mortality Rate
6%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Disease
42%
Chronic Obstructive Lung Disease
38%
Coronavirinae
33%
Cytokine Storm
16%
Eosinophilia
16%
Omalizumab
16%
Tezepelumab
16%
Syndrome
16%
Artemisia vulgaris
16%
Chronic Urticaria
16%
Benralizumab
16%
Allergic Asthma
16%
Immediate Type Hypersensitivity
16%
15 Hydroxyicosatetraenoic Acid
16%
Prevalence
8%
Food Allergen
8%
Placebo
7%
Epileptic Absence
6%
Mortality Rate
5%